-
1 Comment
Krystal Biotech, Inc is currently in a long term uptrend where the price is trading 5.4% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Krystal Biotech, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 196.0% to $-16M since the same quarter in the previous year.
Finally, its free cash flow fell by 56.8% to $-12M since the same quarter in the previous year.
Based on the above factors, Krystal Biotech, Inc gets an overall score of 2/5.
| CurrencyCode | EUR |
|---|---|
| ISIN | US5011471027 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | F |
| Target Price | 98.43 |
|---|---|
| Market Cap | 4B |
| PE Ratio | 52.77 |
| Beta | 0.75 |
| Dividend Yield | None |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4KB.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
